ABT · Abbott Laboratories · Webcasts, Transcripts & Audio
$108.52
+1.27 (+1.18%)
At close · Nov 13
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$187.95B
Shares
1.73B
Volume · Nov 13
6.2M
Avg daily vol (3M)
8.95M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Abbott Laboratories Webcasts
Earnings calls, investor updates, investor days and conferences for Abbott Laboratories (ABT), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-10-21
Abbott Laboratories (ABT) Q3 2026 Earnings Call Transcript
Confident tone
Nutrition separation and portfolio repositioning
Innovation pipeline and new product launches
Diabetes growth, reimbursement, and pricing pressure
Revenue
$13.01B
▲ 14.5% YoY Diluted EPS
$0.53
▼ 43.6% YoY Gross margin
56.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q2
2026-07-16
Abbott Laboratories (ABT) Q2 2026 Earnings Call Transcript
Confident tone
Guidance and EPS Outlook
Diagnostics
Medical Devices / Electrophysiology
Revenue
$12.59B
▲ 13% YoY Diluted EPS
$0.53
▼ 47.5% YoY Gross margin
57.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-04-16
Abbott Laboratories (ABT) Q1 2026 Earnings Call Transcript
Positive tone
Exact Sciences acquisition
China VBP headwinds
Diagnostics / Core Lab
Revenue
$11.16B
▲ 7.8% YoY Diluted EPS
$0.61
▼ 19.7% YoY Gross margin
56.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-01-22
Abbott Laboratories (ABT) Q4 2025 Earnings Call Transcript
Positive tone
Nutrition recovery and volume transition
Medical devices growth and innovation
2026 guidance and tariff exposure
Revenue
$11.46B*
▲ 4.4% YoY Gross margin
57.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-15
Abbott Laboratories (ABT) Q3 2025 Earnings Call Transcript
Confident tone
China Diagnostics Headwinds
New Product Launches
Structural Heart Portfolio
Revenue
$11.37B
▲ 6.9% YoY Diluted EPS
$0.94
▲ 0% YoY Gross margin
55.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-07-17
Abbott Laboratories (ABT) Q2 2025 Earnings Call Transcript
Confident tone
M&A Opportunities
Medical Devices Growth
Diabetes Care / Libre
Revenue
$11.14B
▲ 7.4% YoY Diluted EPS
$1.01
▲ 36.5% YoY Gross margin
56.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-04-16
Abbott Laboratories (ABT) Q1 2025 Earnings Call Transcript
Positive tone
Tariffs and mitigation
Electrophysiology and structural heart
Diversified business model and execution
Revenue
$10.36B
▲ 4% YoY Diluted EPS
$0.76
▲ 8.6% YoY Gross margin
56.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-01-22
Abbott Laboratories (ABT) Q4 2024 Earnings Call Transcript
Confident tone
Quarterly and Full-Year Financial Performance
2025 Guidance and Outlook
Medical Devices / MedTech Portfolio
Revenue
$10.97B*
▲ 7.2% YoY Gross margin
55.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-16
Abbott Laboratories (ABT) Q3 2024 Earnings Call Transcript
Confident tone
Diabetes Care / FreeStyle Libre
Gross Margin Expansion
Electrophysiology Pipeline
Revenue
$10.63B
▲ 4.9% YoY Diluted EPS
$0.94
▲ 14.6% YoY Gross margin
55.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-18
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
Confident tone
Structural heart / Amulet
Established Pharmaceuticals and biosimilars
Nutrition (including NEC litigation)
Revenue
$10.38B
▲ 4% YoY Diluted EPS
$0.74
▼ 5.1% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-04-17
Abbott Laboratories (ABT) Q1 2024 Earnings Call Transcript
Confident tone
Pipeline and Product Approvals
Structural Heart Portfolio
Nutrition Business
Revenue
$9.96B
▲ 2.2% YoY Diluted EPS
$0.70
▼ 6.7% YoY Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-24
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript
Confident tone
COVID Testing Wind-Down and Base Business Strength
R&D Pipeline and Product Approvals
2024 Guidance and Outlook
Revenue
$10.24B*
▲ 1.5% YoY Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-10-18
Abbott Laboratories (ABT) Q3 2023 Earnings Call Transcript
Revenue
$10.14B
▼ 2.6% YoY Diluted EPS
$0.82
▲ 1.2% YoY Gross margin
54.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-07-20
Abbott Laboratories (ABT) Q2 2023 Earnings Call Transcript
Revenue
$9.98B
▼ 11.4% YoY Diluted EPS
$0.78
▼ 31.6% YoY Gross margin
55.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-04-19
Abbott Laboratories (ABT) Q1 2023 Earnings Call Transcript
Revenue
$9.75B
▼ 18.1% YoY Diluted EPS
$0.75
▼ 45.3% YoY Gross margin
55.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-25
Abbott Laboratories (ABT) Q4 2022 Earnings Call Transcript
Revenue
$10.09B*
▼ 12% YoY Gross margin
54.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-10-19
Abbott Laboratories (ABT) Q3 2022 Earnings Call Transcript
Revenue
$10.41B
▼ 4.7% YoY Diluted EPS
$0.81
▼ 30.8% YoY Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-07-20
Abbott Laboratories (ABT) Q2 2022 Earnings Call Transcript
Revenue
$11.26B
▲ 10.1% YoY Diluted EPS
$1.14
▲ 72.7% YoY Gross margin
56.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-04-20
Abbott Laboratories (ABT) Q1 2022 Earnings Call Transcript
Revenue
$11.89B
▲ 13.8% YoY Diluted EPS
$1.37
▲ 37% YoY Gross margin
58.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-26
Abbott Laboratories (ABT) Q4 2021 Earnings Call Transcript
Revenue
$11.47B*
▲ 7.2% YoY Gross margin
58.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-10-20
Abbott Laboratories (ABT) Q3 2021 Earnings Call Transcript
Revenue
$10.93B
▲ 23.4% YoY Diluted EPS
$1.17
▲ 69.6% YoY Gross margin
59.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-07-22
Abbott Laboratories (ABT) Q2 2021 Earnings Call Transcript
Revenue
$10.22B
▲ 39.5% YoY Diluted EPS
$0.66
▲ 120% YoY Gross margin
51.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-20
Abbott Laboratories (ABT) Q1 2021 Earnings Call Transcript
Revenue
$10.46B
▲ 35.3% YoY Diluted EPS
$1.00
▲ 222.6% YoY Gross margin
57.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-27
Abbott Laboratories (ABT) Q4 2020 Earnings Call Transcript
Revenue
$10.70B*
▲ 28.7% YoY Gross margin
58.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-10-21
Abbott Laboratories (ABT) Q3 2020 Earnings Call Transcript
Revenue
$8.85B
▲ 9.6% YoY Diluted EPS
$0.69
▲ 30.2% YoY Gross margin
55.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-07-16
Abbott Laboratories (ABT) Q2 2020 Earnings Call Transcript
Revenue
$7.33B
▼ 8.2% YoY Diluted EPS
$0.30
▼ 46.4% YoY Gross margin
55.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-16
Abbott Laboratories (ABT) Q1 2020 Earnings Call Transcript
Revenue
$7.73B
▲ 2.5% YoY Diluted EPS
$0.31
▼ 18.4% YoY Gross margin
57.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-22
Abbott Laboratories (ABT) Q4 2019 Earnings Call
Revenue
$8.31B
▲ 7.1% YoY Diluted EPS
$0.59
▲ 59.5% YoY Gross margin
52.9%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 webcasts
Key facts
CIK
1800
CUSIP
002824100
13F (30d)
2389 filings
2259 filers
Visit website
Investor relations